Welcome and Introductions
Opening Remarks Peter Hillmen
History of CLL Gerald Marti
Session 1:
The CLL (Epi)genome
Chair(s): Christopher Oakes, and Tatjana Stankovic
Overview of the CLL Genome Jonathan Strefford
The Epigenetic Features of CLL:
DNA Methylation Christoph Plass
Insights From Tertiary Structure, Chromatin
Modifications, and Nuclear Organization José Ignacio Martín-Subero
*Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification (2086) Kate Ridout
*BIRC3 loss accelerates leukemic progression through activation of the non-canonical NF-kB signaling of del(11q) CLL cells (2133) Miguel Quijada-Álamo
**Leukemia specific delivery of miR29b induces epigenetic reprogramming with cell cycle arrest and therapeutic benefit in Chronic Lymphocytic Leukemia (2188) Natarajan Muthusamy
**Cooperation between SF3B1 mutation and ATM deletion in the development of CLL (2194) Lili Wang
Session 2:
The CLL (Epi)genome (cont.)
Chair(s): Sarka Pospisilova, and Deepa Sampath
Keynote
Evolution and Mathematical Modelling of
Cancer Genomes Gad Getz
Presentation
Not Available
Functional Implications of Genomic Lesions Catherine Wu
The Impact of Regulatory RNA Molecules Marek Mráz
ATM: Pathway, Lesions, and Targeting Tatjana Stankovic
*Effect of second-generation BTK inhibitors on the functionality of macrophages and neutrophils from CLL patients. (2088) Mercedes Borge
*Pyroptosis as a drugable cell death pathway in Chronic Lymphocytic Leukemia: The other side of inflammation. (2052) Pablo Oppezzo
**Clinical impact of clonal and subclonal TP53 mutations and deletions in chronic lymphocytic leukemia: an Italian multicenter experience (2130) Riccardo Bomben
**Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact (2136) Jitka Malcikova
Session 3:
The B-Cell Receptor
Chair(s): Andrew Steele, and Jan Burger
Role of the B-Cell Receptor in B-Cell
Oncogenesis Stefano Casola
Dissecting CLL Immunogenetics and
Emerging B-Cell Receptor Stereotypes Kostas Stamatopoulos
CLL-Specific Aspects of B-Cell Receptor
Signaling Graham Packham
*Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL. (1904) Adam Linley
*Functional interplay between the B-cell receptor and NOTCH1 in Chronic Lymphocytic Leukemia and in Richter’s syndrome (2065) Francesca Arruga
**Targeting MDSCs in CLL-bearing mice by suppressing the synthesis of secretory IgM via activation of RIDD (1987) Chih-Chi Hu
**Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia (2047) Pablo Morande
**Distinct Immune Signatures in Chronic Lymphocytic Leukemia and Richter Syndrome (2062) Yucai Wang
Session 4:
Microenvironment and Models of CLL
Chair(s): Christopther Pepper, and Varsha Gandhi
Linking the Microenvironment With CLL
Models Nicholas Chiorazzi
In Vitro Modelling of the CLL
Microenvironment Alan Ramsay
Murine and Xenograft Models of CLL Shih-Shih Chen
Role of NOTCH1 in CLL and in Richter’s Transformation Silvia Deaglio
*Mechanisms of Ibrutinib resistance in the Eµ-TCL-1 mouse model of chronic lymphocytic leukemia (2124) Martina Seiffert
*3D-culture of CLL cells in bioreactor identifies the bone marrow as a key regulator of HS1 function in response to Ibrutinib (1932) Cristina Scielzo
Presentation
Not Available
**Analyzing the mutational landscape of two CLL mouse models overexpressing AID identifies proliferative fraction-associated tumor genes involved in leukemic development and progression (2049) Pablo Morande
**Modelling Chronic Lymphocytic Leukemia microenvironment in vitro by exploiting newly-established 3D systems (2006) Francesca Vittoria Sbrana
**Chronic lymphocytic leukemia remodels the fibroblastic reticular network that contributes to immunosuppression in the tumor microenvironment (2166) Natalia Couto-Francisco
Presentation
Not Available
**IL10-producing CD38hi B-regulatory cells drive the immunosuppressive microenvironment in CLL and can be targeted with anti-CD38 immunotherapy (2193) Alak Manna
Presentation
Not Available
sun
Sunday, 22 September
Session 5:
Innovations in the Assessment of CLL
Chair(s): Alessandra Ferrajoli, and Nicole Lamanna
Laboratory Assessment of CLL, Including MRD
as an End Point Andrew Rawstron
Molecular Characterization of CLL Richard Rosenquist Brandell
Presentation
Not Available
Clinical Assessment of CLL Carol Moreno
Critical Assessment and New Development of
Prognostic Scoring Systems Barbara Eichhorst
*Gene expression signatures predict time-to-progression after front-line chemoimmunotherapy for CLL (1925) Kevin Coombes
*Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind randomized CLL12 trial. (1938) Petra Langerbeins
**Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia (2089) Thomas Lew
**Predicting tumor lysis syndrome in venetoclax-treated CLL patients (2008) Anthony Mato
Session 6:
Initial Therapy
Chair(s): Steven Coutre, and Adrian Bloor
Early Intervention: Can We Justify It and What
End Points Should We Consider? Petra Langerbeins
Current Initial Treatment of CLL – for Young
Patients Florence Cymbalista
Current Initial Treatment of CLL – for Elderly
Patients Valentin Goede
Treatment of CLL from 2019 Onwards: E1912 Trial Tait Shanafelt
Presentation
Not Available
Treatment of CLL from 2019 Onwards: Alliance Trial Danielle Brander
Treatment of CLL from 2019 Onwards: iLLUMINATE Trial Alessandra Tedeschi
Treatment of CLL from 2019 Onwards: CLL14 Trial Kirsten Fischer
*Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged ≥65 year of age: results with 5 years of follow-up for the RESONATE-2 study (1956) Alessandra Tedeschi
*Obinutuzumab and ibrutinib treatment induction followed by a minimal residual disease-driven strategy in chronic lymphocytic leukaemia: long-term results in the ICLL-07 FILO trial (1962) Anne-Sophie Michallet
Presentation
Not Available
**Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood resulting in improved Progression-free survival: Results of UK NCRI Phase II/III GALACTIC trial (2121) Talha Munir
**Long-term efficacy and safety of maintenance with lenalidomide in patients with chronic lymphocytic leukaemia and a high risk of progression after first-line immunochemotherapy (2017) Moritz Fürstenau
Keynote
Overview of Clonal Evolution and Genomic Instability in CLL and Implications for Therapy Daniel Landau
Presentation
Not Available
Session 7:
Resistance Mechanisms
Chair(s): Bryone Kuss, and Loic Ysebaert
Development of Resistance to B-Cell Receptor
Inhibition Jennifer Woyach
Presentation
Not Available
Development of Resistance to BCL2 Inhibition Mary Ann Anderson
*Prevalence of BTK and PLCG2 mutations in chronic lymphocytic leukemia patients relapsing on ibrutinib: a European Research Initiative on CLL (ERIC) real-world study (2098) Lesley-Ann Sutton
Presentation
Not Available
*High surface tumor IgM levels associate with reduced response duration and with BTK bypass during ibrutinib therapy in CLL patients (2195) Giorgia Chiodin
Presentation
Not Available
**CD8+ T-cell exhaustion induced by leukemic cells mediates progression in Chronic Lymphocytic Leukemia (CLL) (2096) Isabel Jiménez
Binet/Rai Medal Presentation
Presentation
Not Available
mon
Monday, 23 September
Session 8:
Therapy of Relapsed/Refractory CLL
Chair(s): Jacqueline Barrientos, and Barbara Eichhorst
B-Cell Receptor-Inhibitor Therapy in Relapsed/
Refractory Disease Susan O’Brien
BCL2-Inhibitor-Based Therapy and MRD in
Relapsed/Refractory Disease John Seymour
Novel Combinations and MRD in Relapsed/
Refractory Disease Matthew Davids
Defining Duration of Therapy: Is There a Role
for MRD? Talha Munir
*Venetoclax combined with ibrutinib based on a minimal residual disease-guided approach in relapsed/refractory chronic lymphocytic leukemia: results of the IMPROVE study (2068) Lydia Scarfo
Presentation
Not Available
*Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study (2143) Talha Munir
**Biological responses to ibrutinib plus venetoclax in the Bloodwise TAP CLARITYstudy (2163) Andrew Rawstron
**Pneumocystis jirovecii pneumonia and invasive fungal infection incidence and institutional prophylaxis practices in CLL patients treated with BTK inhibitors (1941) Christine Ryan
Session 9:
Novel Strategies in Rel/Refr CLL
Chair(s): George Follows, and Adrian Wiestner
Evolution of Small Molecule Inhibitors:
New vs Old John Byrd
Presentation
Not Available
Updates on Immune Therapy Strategies,
Including CAR T-Cell Therapy and Stem Cell
Transplant Katy Rezvani
*ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158) Wojciech Jurczak
**A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy (1943) Danielle Brander
**Biology and targeting of mutant p53 in CLL (2172) Janani Ravikrishnan
Debate: Future Management of CLL:
Is There a Role for Cellular Therapy? Moderator: Anna Schuh
David Maloney (CAR T)
Johannes Schetelig (SCT)
Matt Davids (Novel-Novel)
Session 10:
Real-World Data and Registries
Chair(s): Neil Kay, and Eva Kimby
CLL Clinical Genomics: Overview of the
National Programmes in Sweden, the US, the
UK, and France Anna Schuh
Geographic Diversity and Management of CLL
in South American Patients Carlos Sérgio Chiattone
Presentation
Not Available
Geographic Diversity and Management of CLL
in African Patients Norah Akinola
Geographic Diversity and Management of CLL
in Indian Patients Abraham Varghese
Geographic Diversity and Management of CLL
in Chinese Patients Shenmiao Yang
Session 11:
iwCLL UPDATES
Chair: Peter Hillmen
Reorganization of the iwCLL Michael Hallek
An Update From the European Research
Initiative on CLL (ERIC) Paolo Ghia
Current Efforts From European and US
Real-World Data Christopher Fox (EU) and Anthony Mato (US)
Presentation
Not Available
Closing Comments Peter Hillmen
2019 Presentations Access
Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.